These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Private company leaders looking to sell reported that tax on recognized gains (88%) and transfer taxes (87%) were major concerns, per a Deloitte survey.